Illinois General Assembly - Full Text of HB5079
Illinois General Assembly

Previous General Assemblies

Full Text of HB5079  96th General Assembly

HB5079enr 96TH GENERAL ASSEMBLY

  
  
  

 


 
HB5079 Enrolled LRB096 18956 RPM 34344 b

1     AN ACT concerning insurance.
 
2     Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
 
4     Section 5. The Health Carrier External Review Act is
5 amended by changing Section 35 as follows:
 
6     (215 ILCS 180/35)
7     (This Section may contain text from a Public Act with a
8 delayed effective date)
9     Sec. 35. Standard external review.
10     (a) Within 4 months after the date of receipt of a notice
11 of an adverse determination or final adverse determination, a
12 covered person or the covered person's authorized
13 representative may file a request for an external review with
14 the health carrier.
15     (b) Within 5 business days following the date of receipt of
16 the external review request, the health carrier shall complete
17 a preliminary review of the request to determine whether:
18         (1) the individual is or was a covered person in the
19     health benefit plan at the time the health care service was
20     requested or at the time the health care service was
21     provided;
22         (2) the health care service that is the subject of the
23     adverse determination or the final adverse determination

 

 

HB5079 Enrolled - 2 - LRB096 18956 RPM 34344 b

1     is a covered service under the covered person's health
2     benefit plan, but the health carrier has determined that
3     the health care service is not covered because it does not
4     meet the health carrier's requirements for medical
5     necessity, appropriateness, health care setting, level of
6     care, or effectiveness;
7         (3) the covered person has exhausted the health
8     carrier's internal grievance process as set forth in this
9     Act;
10         (4) for appeals relating to a determination based on
11     treatment being experimental or investigational, the
12     requested health care service or treatment that is the
13     subject of the adverse determination or final adverse
14     determination is a covered benefit under the covered
15     person's health benefit plan except for the health
16     carrier's determination that the service or treatment is
17     experimental or investigational for a particular medical
18     condition and is not explicitly listed as an excluded
19     benefit under the covered person's health benefit plan with
20     the health carrier and that the covered person's health
21     care provider, who ordered or provided the services in
22     question and who is licensed under the Medical Practice Act
23     of 1987 is a physician licensed to practice medicine in all
24     its branches, has certified that one of the following
25     situations is applicable:
26             (A) standard health care services or treatments

 

 

HB5079 Enrolled - 3 - LRB096 18956 RPM 34344 b

1         have not been effective in improving the condition of
2         the covered person;
3             (B) standard health care services or treatments
4         are not medically appropriate for the covered person;
5             (C) there is no available standard health care
6         service or treatment covered by the health carrier that
7         is more beneficial than the recommended or requested
8         health care service or treatment;
9             (D) the health care service or treatment is likely
10         to be more beneficial to the covered person, in the
11         health care provider's opinion, than any available
12         standard health care services or treatments; or
13             (E) that scientifically valid studies using
14         accepted protocols demonstrate that the health care
15         service or treatment requested is likely to be more
16         beneficial to the covered person than any available
17         standard health care services or treatments; and
18         (5) the covered person has provided all the information
19     and forms required to process an external review, as
20     specified in this Act.
21     (c) Within one business day after completion of the
22 preliminary review, the health carrier shall notify the covered
23 person and, if applicable, the covered person's authorized
24 representative in writing whether the request is complete and
25 eligible for external review. If the request:
26         (1) is not complete, the health carrier shall inform

 

 

HB5079 Enrolled - 4 - LRB096 18956 RPM 34344 b

1     the covered person and, if applicable, the covered person's
2     authorized representative in writing and include in the
3     notice what information or materials are required by this
4     Act to make the request complete; or
5         (2) is not eligible for external review, the health
6     carrier shall inform the covered person and, if applicable,
7     the covered person's authorized representative in writing
8     and include in the notice the reasons for its
9     ineligibility.
10     The notice of initial determination of ineligibility shall
11 include a statement informing the covered person and, if
12 applicable, the covered person's authorized representative
13 that a health carrier's initial determination that the external
14 review request is ineligible for review may be appealed to the
15 Director by filing a complaint with the Director.
16     Notwithstanding a health carrier's initial determination
17 that the request is ineligible for external review, the
18 Director may determine that a request is eligible for external
19 review and require that it be referred for external review. In
20 making such determination, the Director's decision shall be in
21 accordance with the terms of the covered person's health
22 benefit plan and shall be subject to all applicable provisions
23 of this Act.
24     (d) Whenever a request is eligible for external review the
25 health carrier shall, within 5 business days:
26         (1) assign an independent review organization from the

 

 

HB5079 Enrolled - 5 - LRB096 18956 RPM 34344 b

1     list of approved independent review organizations compiled
2     and maintained by the Director; and
3         (2) notify in writing the covered person and, if
4     applicable, the covered person's authorized representative
5     of the request's eligibility and acceptance for external
6     review and the name of the independent review organization.
7     The health carrier shall include in the notice provided to
8 the covered person and, if applicable, the covered person's
9 authorized representative a statement that the covered person
10 or the covered person's authorized representative may, within 5
11 business days following the date of receipt of the notice
12 provided pursuant to item (2) of this subsection (d), submit in
13 writing to the assigned independent review organization
14 additional information that the independent review
15 organization shall consider when conducting the external
16 review. The independent review organization is not required to,
17 but may, accept and consider additional information submitted
18 after 5 business days.
19     (e) The assignment of an approved independent review
20 organization to conduct an external review in accordance with
21 this Section shall be made from those approved independent
22 review organizations qualified to conduct external review as
23 required by Sections 50 and 55 of this Act.
24     (f) Upon assignment of an independent review organization,
25 the health carrier or its designee utilization review
26 organization shall, within 5 business days, provide to the

 

 

HB5079 Enrolled - 6 - LRB096 18956 RPM 34344 b

1 assigned independent review organization the documents and any
2 information considered in making the adverse determination or
3 final adverse determination; in such cases, the following
4 provisions shall apply:
5         (1) Except as provided in item (2) of this subsection
6     (f), failure by the health carrier or its utilization
7     review organization to provide the documents and
8     information within the specified time frame shall not delay
9     the conduct of the external review.
10         (2) If the health carrier or its utilization review
11     organization fails to provide the documents and
12     information within the specified time frame, the assigned
13     independent review organization may terminate the external
14     review and make a decision to reverse the adverse
15     determination or final adverse determination.
16         (3) Within one business day after making the decision
17     to terminate the external review and make a decision to
18     reverse the adverse determination or final adverse
19     determination under item (2) of this subsection (f), the
20     independent review organization shall notify the health
21     carrier, the covered person and, if applicable, the covered
22     person's authorized representative, of its decision to
23     reverse the adverse determination.
24     (g) Upon receipt of the information from the health carrier
25 or its utilization review organization, the assigned
26 independent review organization shall review all of the

 

 

HB5079 Enrolled - 7 - LRB096 18956 RPM 34344 b

1 information and documents and any other information submitted
2 in writing to the independent review organization by the
3 covered person and the covered person's authorized
4 representative.
5     (h) Upon receipt of any information submitted by the
6 covered person or the covered person's authorized
7 representative, the independent review organization shall
8 forward the information to the health carrier within 1 business
9 day.
10         (1) Upon receipt of the information, if any, the health
11     carrier may reconsider its adverse determination or final
12     adverse determination that is the subject of the external
13     review.
14         (2) Reconsideration by the health carrier of its
15     adverse determination or final adverse determination shall
16     not delay or terminate the external review.
17         (3) The external review may only be terminated if the
18     health carrier decides, upon completion of its
19     reconsideration, to reverse its adverse determination or
20     final adverse determination and provide coverage or
21     payment for the health care service that is the subject of
22     the adverse determination or final adverse determination.
23     In such cases, the following provisions shall apply:
24             (A) Within one business day after making the
25         decision to reverse its adverse determination or final
26         adverse determination, the health carrier shall notify

 

 

HB5079 Enrolled - 8 - LRB096 18956 RPM 34344 b

1         the covered person and if applicable, the covered
2         person's authorized representative, and the assigned
3         independent review organization in writing of its
4         decision.
5             (B) Upon notice from the health carrier that the
6         health carrier has made a decision to reverse its
7         adverse determination or final adverse determination,
8         the assigned independent review organization shall
9         terminate the external review.
10     (i) In addition to the documents and information provided
11 by the health carrier or its utilization review organization
12 and the covered person and the covered person's authorized
13 representative, if any, the independent review organization,
14 to the extent the information or documents are available and
15 the independent review organization considers them
16 appropriate, shall consider the following in reaching a
17 decision:
18         (1) the covered person's pertinent medical records;
19         (2) the covered person's health care provider's
20     recommendation;
21         (3) consulting reports from appropriate health care
22     providers and other documents submitted by the health
23     carrier, the covered person, the covered person's
24     authorized representative, or the covered person's
25     treating provider;
26         (4) the terms of coverage under the covered person's

 

 

HB5079 Enrolled - 9 - LRB096 18956 RPM 34344 b

1     health benefit plan with the health carrier to ensure that
2     the independent review organization's decision is not
3     contrary to the terms of coverage under the covered
4     person's health benefit plan with the health carrier;
5         (5) the most appropriate practice guidelines, which
6     shall include applicable evidence-based standards and may
7     include any other practice guidelines developed by the
8     federal government, national or professional medical
9     societies, boards, and associations;
10         (6) any applicable clinical review criteria developed
11     and used by the health carrier or its designee utilization
12     review organization; and
13         (7) the opinion of the independent review
14     organization's clinical reviewer or reviewers after
15     considering items (1) through (6) of this subsection (i) to
16     the extent the information or documents are available and
17     the clinical reviewer or reviewers considers the
18     information or documents appropriate; and
19         (8) for a denial of coverage based on a determination
20     that the health care service or treatment recommended or
21     requested is experimental or investigational, whether and
22     to what extent:
23             (A) the recommended or requested health care
24         service or treatment has been approved by the federal
25         Food and Drug Administration, if applicable, for the
26         condition;

 

 

HB5079 Enrolled - 10 - LRB096 18956 RPM 34344 b

1             (B) medical or scientific evidence or
2         evidence-based standards demonstrate that the expected
3         benefits of the recommended or requested health care
4         service or treatment is more likely than not to be
5         beneficial to the covered person than any available
6         standard health care service or treatment and the
7         adverse risks of the recommended or requested health
8         care service or treatment would not be substantially
9         increased over those of available standard health care
10         services or treatments; or
11             (C) the terms of coverage under the covered
12         person's health benefit plan with the health carrier to
13         ensure that the health care service or treatment that
14         is the subject of the opinion is experimental or
15         investigational would otherwise be covered under the
16         terms of coverage of the covered person's health
17         benefit plan with the health carrier.
18     (j) Within 5 days after the date of receipt of all
19 necessary information, the assigned independent review
20 organization shall provide written notice of its decision to
21 uphold or reverse the adverse determination or the final
22 adverse determination to the health carrier, the covered person
23 and, if applicable, the covered person's authorized
24 representative. In reaching a decision, the assigned
25 independent review organization is not bound by any claim
26 determinations reached prior to the submission of information

 

 

HB5079 Enrolled - 11 - LRB096 18956 RPM 34344 b

1 to the independent review organization. In such cases, the
2 following provisions shall apply:
3         (1) The independent review organization shall include
4     in the notice:
5             (A) a general description of the reason for the
6         request for external review;
7             (B) the date the independent review organization
8         received the assignment from the health carrier to
9         conduct the external review;
10             (C) the time period during which the external
11         review was conducted;
12             (D) references to the evidence or documentation,
13         including the evidence-based standards, considered in
14         reaching its decision;
15             (E) the date of its decision; and
16             (F) the principal reason or reasons for its
17         decision, including what applicable, if any,
18         evidence-based standards that were a basis for its
19         decision.
20         (2) For reviews of experimental or investigational
21     treatments, the notice shall include the following
22     information:
23             (A) a description of the covered person's medical
24         condition;
25             (B) a description of the indicators relevant to
26         whether there is sufficient evidence to demonstrate

 

 

HB5079 Enrolled - 12 - LRB096 18956 RPM 34344 b

1         that the recommended or requested health care service
2         or treatment is more likely than not to be more
3         beneficial to the covered person than any available
4         standard health care services or treatments and the
5         adverse risks of the recommended or requested health
6         care service or treatment would not be substantially
7         increased over those of available standard health care
8         services or treatments;
9             (C) a description and analysis of any medical or
10         scientific evidence considered in reaching the
11         opinion;
12             (D) a description and analysis of any
13         evidence-based standards;
14             (E) whether the recommended or requested health
15         care service or treatment has been approved by the
16         federal Food and Drug Administration, for the
17         condition;
18             (F) whether medical or scientific evidence or
19         evidence-based standards demonstrate that the expected
20         benefits of the recommended or requested health care
21         service or treatment is more likely than not to be more
22         beneficial to the covered person than any available
23         standard health care service or treatment and the
24         adverse risks of the recommended or requested health
25         care service or treatment would not be substantially
26         increased over those of available standard health care

 

 

HB5079 Enrolled - 13 - LRB096 18956 RPM 34344 b

1         services or treatments; and
2             (G) the written opinion of the clinical reviewer,
3         including the reviewer's recommendation as to whether
4         the recommended or requested health care service or
5         treatment should be covered and the rationale for the
6         reviewer's recommendation.
7         (3) In reaching a decision, the assigned independent
8     review organization is not bound by any decisions or
9     conclusions reached during the health carrier's
10     utilization review process or the health carrier's
11     internal grievance or appeals process.
12         (4) Upon receipt of a notice of a decision reversing
13     the adverse determination or final adverse determination,
14     the health carrier immediately shall approve the coverage
15     that was the subject of the adverse determination or final
16     adverse determination.
17 (Source: P.A. 96-857, eff. 7-1-10.)
 
18     Section 95. No acceleration or delay. Where this Act makes
19 changes in a statute that is represented in this Act by text
20 that is not yet or no longer in effect (for example, a Section
21 represented by multiple versions), the use of that text does
22 not accelerate or delay the taking effect of (i) the changes
23 made by this Act or (ii) provisions derived from any other
24 Public Act.